Reference
Regulatory status
Last updated: July 2026
The FDA has not approved, endorsed, certified, or recommended any product sold on this site.
Nothing on this page should be read as suggesting otherwise. What follows is a summary of a public regulatory process concerning certain molecules — not a statement about our vials, our supplier, or our quality.
What 503A means
Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding pharmacies — the pharmacies that mix a preparation for an individual patient against a prescription. A substance has to appear on an approved list before a 503A pharmacy may compound with it.
"Nominated for pharmacy compounding" means someone has petitioned the FDA to add a substance to that list. Anyone may nominate: compounders, pharmacy trade groups, manufacturers. A nomination is a request, not a finding.
What happened in 2026
In April 2026 the FDA removed twelve peptides from its Category 2 "do not compound" list after the nominations behind those listings were withdrawn.
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee — outside pharmacists and physicians, meeting in public — voted to recommend six of seven peptides for the 503A list. BPC-157 and TB-500 were among those recommended. Semax was not.
What that vote is not
The committee is advisory. Its vote carries no force of law. For anything to change, the FDA must accept the recommendation, publish a proposed rule, run notice-and-comment rulemaking, and issue a final rule. None of that has happened.
It is also not a finding of safety or efficacy. During the meeting FDA scientists described limited evidence and raised safety concerns, returning repeatedly to the difficulty of establishing what these compounds reliably are from one supplier to the next. Press coverage noted that some panel members had ties to the peptide industry.
And it concerns molecules, not products. No vial from any vendor — ours included — was reviewed, tested, or approved.
Where our catalog stands
BPC-157 — recommended by the July 2026 committee vote. Carries the 503A chip on its product page.
Wolverine Stack — contains BPC-157 and TB-500, both recommended. The blend itself was never nominated and appears on no list, which is why its marker reads ingredients rather than claiming the blend was reviewed.
Retatrutide, Semaglutide, Tirzepatide, NAD+, GLOW — not part of this review. No regulatory status to cite.
What has not changed
Everything we sell remains for laboratory research use only, and is not for human or animal consumption. Our assay results are still pending and the site makes no purity claim until they arrive. See the Terms of Service.